Zimbru Răzvan-Ionuț, Zimbru Elena-Larisa, Bojin Florina-Maria, Haidar Laura, Andor Minodora, Harich Octavia Oana, Tănasie Gabriela, Tatu Carmen, Mailat Diana-Evelyne, Zbîrcea Iulia-Maria, Hirtie Bogdan, Uța Cristina, Bănărescu Camelia-Felicia, Panaitescu Carmen
Center of Immuno-Physiology and Biotechnologies, Department of Functional Sciences, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Research Center for Gene and Cellular Therapies in the Treatment of Cancer-OncoGen, Timis County Emergency Clinical Hospital "Pius Brinzeu", 156 Liviu Rebreanu Bd., 300723 Timisoara, Romania.
Int J Mol Sci. 2025 Apr 10;26(8):3570. doi: 10.3390/ijms26083570.
Asthma and atherosclerosis are chronic conditions with distinct pathophysiologies, but overlapping inflammatory mechanisms that suggest a potential common regulatory framework. MicroRNAs (miRNAs), small non-coding RNA molecules that modulate gene expression post-transcriptionally, could be key players in linking these disorders. This review outlines how miRNAs contribute to the complex interplay between asthma and atherosclerosis, focusing on key miRNAs involved in inflammatory pathways, immune cell regulation and vascular remodeling. We discuss specific miRNAs, such as miR-155, miR-21 and miR-146a, which have been shown to modulate inflammatory cytokine production and T cell differentiation, impacting respiratory and cardiovascular health. The common miRNAs found in both asthma and atherosclerosis emphasize their role as potential biomarkers, but also as therapeutic targets. Understanding these molecular connections may unlock novel approaches for innovative, integrated treatment strategies that address both conditions and may significantly improve patient outcomes. Further research is needed to explore mechanistic pathways and validate the translational potential of miRNA-based interventions in preclinical and clinical settings.
哮喘和动脉粥样硬化是具有不同病理生理学的慢性疾病,但炎症机制存在重叠,这表明可能存在一个潜在的共同调控框架。微小RNA(miRNA)是一类小的非编码RNA分子,可在转录后调节基因表达,可能是连接这些疾病的关键因素。本综述概述了miRNA如何促成哮喘与动脉粥样硬化之间的复杂相互作用,重点关注参与炎症途径、免疫细胞调节和血管重塑的关键miRNA。我们讨论了特定的miRNA,如miR-155、miR-21和miR-146a,它们已被证明可调节炎症细胞因子的产生和T细胞分化,影响呼吸和心血管健康。在哮喘和动脉粥样硬化中均发现的常见miRNA强调了它们作为潜在生物标志物以及治疗靶点的作用。了解这些分子联系可能会为创新的综合治疗策略带来新方法,这些策略可同时应对这两种疾病,并可能显著改善患者预后。需要进一步研究来探索其机制途径,并在临床前和临床环境中验证基于miRNA的干预措施的转化潜力。